Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | CCR6 | P51684 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | PKLR | P30613 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7573407 | 0.91 | ALDH1A1 (0.54) | KMT2AALDH1A1GAAHPGDCCR6 | |
| SCHEMBL7559714 | 0.81 | CHRM5 (0.46) | KMT2AALDH1A1GAAHPGDMEN1 | |
| SCHEMBL7605168 | 0.80 | ALDH1A1 (0.44) | KMT2AALDH1A1GAAHPGDMEN1 | |
| SCHEMBL7560551 | 0.79 | KMT2A (0.49) | KMT2AALDH1A1GAAHPGDMEN1 | |
| SCHEMBL7565684 | 0.78 | MCOLN3 (0.47) | KMT2AALDH1A1GAAHPGDMEN1 | |
| SCHEMBL4439040 | 0.77 | MCOLN3 (0.49) | KMT2AALDH1A1GAAHPGDMEN1 | |
| SCHEMBL7581593 | 0.74 | SIGMAR1 (0.42) | POLB | |
| SCHEMBL7548283 | 0.74 | SIGMAR1 (0.42) | ALDH1A1POLBL3MBTL1 | |
| SCHEMBL7530370 | 0.73 | ALDH1A1 (0.51) | KMT2AALDH1A1GAAHPGDCCR6 | |
| SCHEMBL7557129 | 0.72 | CYP19A1 (0.41) | KMT2AALDH1A1GAAHPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292203-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION | 2010-11-18 | — | — | US | disclosed |
| US-20100292203-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292203-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | CHRM1, CHRM2, PRSS1 | KMT2A 4458/4885ALDH1A1 4505/4885GAA 1474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.